AB0342 OBSTETRIC AND THROMBOTIC ANTIPHOSPHOLIPID SYNDROME: ARE THEY DIFFERENT ENTITIES?

Background: Several studies showed two main clinical phenotypes of antiphospholipid syndrome (APS): thrombotic (TAPS) and obstetric APS (OAPS). Although they have the same autoantibody profile, one them developed thrombosis other morbidity. Objectives: To study clinical, demographic antibody profile in patients with TAPS OAPS. Methods: we retrospectively evaluated OAPS who were included Argentine Antiphospholipid antibodies registry. We studied both groups. Results: 238 201 (84.81%) female. 122 (60.69 %) fullfilled Sydney classification criteria, 47 (38.52%) 52 (42.62%) 23 (18.85%) had events so excluded this analysis. Arterial Hypertension (HBP) Hyperlipidemia more frequent versus Older age was found as well association Systemic lupus erythematosus (SLE). There no difference between 2 groups, Global Syndrome Score (aGAPSS) higher than 18 (38.3%) at least 1 pregnancy. Mean number pregnancies 2.5 (1.10) 3.84 (1.86) Thrombotic not during pregnancy puerperium. HBP gestational diabetes (GD) related comorbidities TAPS. (n=52) (n=47) P TAPS(n=18) SLE, n (% ) 11 (21.2) 28 (59.6) 0.0002 N % (DE) aGAPSS, mean (RIQ 4 (5) 8 <0.0001 Abortions (<10 weeks) 33 38.4 (36.2) 26.5 (35.3) Age, (DE 39.3 (6.24) 43.1 (13.5) Live Birth 36 33.5 (28.1) 16 72.2 (34.7) HBP, 5 (9.6) 15 (31.9) 0.0121 >37 weeks 21 16.4 (2.38) 61.1 (31.7) Hyperlipidemia, (7.7) 12(25.5) 0.0267 Prematurity <37 >34 8.76 (1.97) 0 - GD, 3(5.8) 2(4.3) 0.9999 <34 9 6.37 (1.49) 1.39 (5.89) Obesity, (15.4) (8.5) 0.2912 Pre eclampsia >34-<37 0.490 (0.0350) 4.6 3 ( 0.138) Smoking, (21.1) 13 (27.6) 0.4019 Placental Hematoma 1.86 (8.18) 2.78 (11.8) Sedentary lifestyle, (30.8) 17 0.8486 Abruptio Placentae 1.96 (9.80) 4.17 (12.9) Triple Positivity 9.6 8.5 0.8323 Normal delivery 20 17.8 (27.9) 14 47.7 (33.9) Double 1.9 6.4 Cesarean section 22 17.2 (21.6) 11.1 (32.3) Simple 29 38.5 19 40.4 Urgent 9.80 (20.3) 12.5 (24.6) GD 1.37 (7.49) 6 3.46 (10.3) 10.2 (26.3) Conclusion: Antibody similar However, manifestations cardiovascular risk different. These results should be prospective studies. Disclosure Interests: None declared